Strategic partnerships yet to fully catch on, Tufts report finds

By Zachary Brennan contact

- Last updated on GMT

Sponsors continue to rely on a mix of outsourcing models.
Sponsors continue to rely on a mix of outsourcing models.

Related tags: Clinical trial

Although a growing number of sponsors and CROs have managed strategic relationships for as many as five years, sponsors still rely on a mix of outsourcing approaches to tackle their clinical programs, according to a new report.

An analysis from the Tufts Center for the Study of Drug Development of 43 Phase II and III clinical studies found that, in each case, sponsors relied on a mix of transactional and strategic relationships, as well as in-house capabilities.

Old habits, including the long-held view by sponsors that CROs are commodity service providers requiring substantial oversight, are slow to change​,” according to the report.

Ken Getz, Director of Sponsored Research Programs & Research at Tufts CSDD, told Outsourcing-Pharma.com: “Sponsors are relying on a mix of approaches to hedge risk and to accommodate a variety of approaches simultaneously; many that were implemented years ago but that support legacy activity.  The problem is that a mixed approach prevents sponsor companies from realizing the conceptual promise and value of integrated, strategic relationships​.”

Interviews across nine major pharma companies by the center also found that sponsors will increase their use of external service providers in 2014 even though improvement in performance, quality, and cost has been elusive. This has been due largely to inconsistent sponsor management of external service providers, which has stymied integration of strategic outsourcing relationships.

Breakdown

Key takeaways from the study include:

  • Nearly all clinical studies outsourced site monitoring, and for an overwhelming majority of studies, site identification and selection;
  • Data management, medical monitoring, patient recruitment and retention, and statistical analyses were outsourced in more than 70% of trials;
  • Internal sponsor staff most frequently manages protocol design and regulatory affairs;
  • No sponsors used a single source to manage all outsourced functional areas; and
  • For studies that were outsourced, screen failure rates were higher and the frequency of protocol amendments was lower.

Despite an overall reluctance to push to more strategic relationships, sponsors continue to refine relationship structures, modify internal team involvement and composition, and adjust the coordination, integration, and oversight of outsourced functions.

We’re finding that organizations are not standing still – they’re very committed to seeing these relationships work and many are trying to refine the model; to identify areas where they can collaborate more effectively​,” Getz told us.

Key issues, however, remain, including: how to engage with, and leverage, the right external partners; how to manage and motivate internal staff; and how to cooperatively manage the relationships.

Related news

Show more

Related products

show more

Paper vs ePRO Data Collection Methods

Paper vs ePRO Data Collection Methods

Signant Health | 19-Oct-2021 | Technical / White Paper

Are you curious why more Sponsors choose digital data collection methods over the traditional pen and paper? Read this recent white paper to discover the...

GLP Tissue Cross Reactivity Testing

GLP Tissue Cross Reactivity Testing

Precision for Medicine | 11-Oct-2021 | Product Brochure

Precision for Medicine's unique combination of research services and tissue procurement capabilities form the pillars of our GLP Tissue Cross Reactivity...

Automating clinical trials for success

Automating clinical trials for success

Formedix | 06-Oct-2021 | Technical / White Paper

This article gives gives a brief overview of why automation is absolutely essential for clinical trial success.

Related suppliers

Follow us

Products

View more

Webinars